<DOC>
	<DOCNO>NCT00328432</DOCNO>
	<brief_summary>To assess effect short term administration celecoxib 400 mg bid biopsy reexcision .</brief_summary>
	<brief_title>A Study Women With Early Diagnosis Breast Cancer , Taking Celecoxib Between Biopsy Lumpectomy/Mastectomy</brief_title>
	<detailed_description>A double blind randomize study celecoxib 400 mg bid versus placebo newly diagnose breast cancer . Assessment modulation tissue marker ( Ki-67 , ER , VEGF , PR , etc . ) serum marker ( estradiol , estrone , SHBG , etc . ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>woman recent diagnosis T1 T2 noninvasive breast cancer large core needle excisional biopsy confirmation tissue process method acceptable protocol sufficient tissue remain postdiagnostic analysis perform research assessment reexcision plan within 10 day 6 week study start prevention tamoxifen raloxifene , must begin administration least six week prior initial biopsy continue reexcision hormone replacement therapy within 90 day prior biopsy prevention tamoxifen raloxifene , must begin administration least six week prior initial biopsy continue reexcision evidence metastatic malignancy kind history asthma , allergy ASA , NSAIDS , celecoxib COX2 inhibitor chronic nononcological condition excision low dose ASA ( 160 mg daily ) 4 week prior biopsy duration study . celecoxib rofecoxib use within one month biopsy history gastrointestinal ulcer ulcerative colitis require treatment current anticoagulant neoadjuvant antihormone chemotherapy treatment follow biopsy prior study entry concurrently participation study aromatase inhibitor six month prior participation concomitant lithium know significant bleeding disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>early breast cancer</keyword>
	<keyword>double-blind randomize placebo-controlled</keyword>
	<keyword>RCT</keyword>
	<keyword>pre-surgical model</keyword>
	<keyword>DCIS model</keyword>
	<keyword>COX-2 inhibitor</keyword>
	<keyword>celecoxib</keyword>
	<keyword>Ki-67 placebo</keyword>
</DOC>